Free Trial

Establishment Labs Q2 2024 Earnings Report

Establishment Labs logo
$32.30 -1.56 (-4.61%)
As of 04:00 PM Eastern

Establishment Labs EPS Results

Actual EPS
-$0.62
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.11
One Year Ago EPS
-$0.65

Establishment Labs Revenue Results

Actual Revenue
$44.12 million
Expected Revenue
$43.10 million
Beat/Miss
Beat by +$1.02 million
YoY Revenue Growth
-9.20%

Establishment Labs Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Remove Ads

Establishment Labs Earnings Headlines

TD Cowen Keeps Their Buy Rating on Establishment Labs Holdings (ESTA)
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Establishment Labs price target lowered to $60 from $75 at TD Cowen
See More Establishment Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Establishment Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Establishment Labs and other key companies, straight to your email.

About Establishment Labs

Establishment Labs (NASDAQ:ESTA), a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

View Establishment Labs Profile

More Earnings Resources from MarketBeat